Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge acts for Medivir in connection with public offer
Mandate

Vinge acts for Medivir in connection with public offer

April 13, 2011

Vinge acts for Medivir in connection with the public offer for BioPhausia AB (publ) (NASDAQ OMX Stockholm) has announced a public offer for BioPhausia AB (publ) (NASDAQ OMX Stockholm). Vinge acts for Medivir.

Vinge’s team is headed by capital markets and public M&A partner Erik Sjöman and includes, among others, Christian Lindhé, Emil Hedberg, Jakob Warren and Markus Larsson. Göran Nyström (public M&A), Kristian Hugmark and Hanna Danwall (competition law) and Mattias Schömer and Maria Doeser (tax) are also on the team.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025